Ironwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $67.02 million for the quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million for the quarter, compared to analysts' expectations of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. On average, analysts expect Ironwood Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:IRWD traded down $0.00 during midday trading on Tuesday, hitting $0.93. 1,388,802 shares of the stock were exchanged, compared to its average volume of 2,554,944. The stock has a market cap of $149.98 million, a P/E ratio of -30.90 and a beta of 0.37. Ironwood Pharmaceuticals has a twelve month low of $0.59 and a twelve month high of $8.23. The company has a 50 day moving average price of $1.20 and a 200-day moving average price of $2.73.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. This trade represents a 6.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

IRWD has been the topic of several recent research reports. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 15th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners lowered their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a report on Monday, April 14th. JMP Securities cut their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a report on Thursday, January 30th. Finally, Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has an average rating of "Hold" and an average price target of $4.78.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.